|
|
||||||||
J Thorac Cardiovasc Surg 1994;108:960-968
© 1994 Mosby, Inc.
CARDIOPULMONARY BYPASS, |
Shanghai, the People's Republic of China
Supported in part by the Chinese Medical Board.
Received for publication Nov. 17, 1993. Accepted for publication April 7, 1994. Address for reprints: Zhi-Gang Zhu, MD, Department of Cardiac Surgery, Zhong Shan Hospital, Shanghai Medical University, Shanghai 200032, the People's Republic of China.
Abstract
The arterial plasma endothelin-1 concentration was substantially more elevated in 15 patients with rheumatic valvular disease and secondary pulmonary hypertension than in healthy volunteers (3.66 ± 2.20 versus 1.17 ± 0.38 pg/ml, mean ± standard deviation; p < 0.01) The preoperative plasma endothelin-1 level was highly correlated with the pulmonary hemodynamics: pulmonary artery systolic pressure (r = 0.94, p < 0.001), pulmonary artery mean pressure (r = 0.86, p < 0.001), pulmonary capillary wedge pressure (r = 0.82, p < 0.001), and pulmonary vascular resistance (r = 0.63, p < 0.02). After valve replacement, the plasma endothelin-1 concentration declined substantially and the pulmonary hemodynamics improved markedly. Two weeks after the operation, the plasma endothelin-1 level in patients (1.26 ± 0.45 pg/ml, mean ± standard deviation) was not statistically different from that in the healthy volunteers. The plasma endothelin-1 concentration continuously increased during the course of cardiopulmonary bypass and peaked after cessation of bypass. The peak plasma endothelin-1 level (13.49 ± 4.60 pg/ml, mean ± standard deviation) positively correlated with the bypass time (r = 0.64, p < 0.02) and negatively correlated with the urine volume during bypass (r = -0.69, p < 0.01). We conclude that (1) increased plasma endothelin-1 might be implicated in the pathogenesis of secondary pulmonary hypertension caused by rheumatic valvular disease and (2) markedly elevated plasma endothelin-1 concentrations might be associated with the mechanism of cardiac or renal dysfunction after prolonged cardiopulmonary bypass. (J THORACCARDIOVASCSURG1994;108:960-8)
This article has been cited by other articles:
![]() |
C. D. Etz, H. A. Welp, T. D.T. Tjan, A. Hoffmeier, E. Weigang, H. H. Scheld, and C. Schmid Medically Refractory Pulmonary Hypertension: Treatment With Nonpulsatile Left Ventricular Assist Devices Ann. Thorac. Surg., May 1, 2007; 83(5): 1697 - 1705. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. L. Sandifer, S. Steinbis, E. L. Jones, and C. Lawrence Pharmacologic Management of Pulmonary Hypertension Associated With Mitral Valve Disease Chest Meeting Abstracts, October 1, 2004; 126(4): 972S - 973S. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. D. Wagner, S. Buz, C. Knosalla, R. Hetzer, and B. Hocher Modulation of Circulating Endothelin-1 and Big Endothelin by Nitric Oxide Inhalation Following Left Ventricular Assist Device Implantation Circulation, September 9, 2003; 108(90101): II-278 - 284. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. R. Bond, B. H. Dorman, M. J. Clair, C. A. Walker, M. L. Pinosky, S. T. Reeves, S. Walton, J. M. Kratz, J. L. Zellner, A. J. Crumbley III, et al. Endothelin-1 during and after cardiopulmonary bypass: Association to graft sensitivity and postoperative recovery J. Thorac. Cardiovasc. Surg., August 1, 2001; 122(2): 358 - 364. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |